← Research · knowledge/companies/ABBV.md
ABBV: AbbVie
_Last updated 2026-10-30 09:00 ET from report. Screening/research, not investment advice._
Business
Pharma: immunology (Skyrizi, Rinvoq), neuroscience, oncology, aesthetics. TRAI cluster 3. Top ρ: JNJ 0.66, LLY 0.64, GILD 0.59.
Catalysts, guidance & news
- Q3 2026: Fri 2026-10-30 BMO, call 9:00 ET. Consensus EPS $3.73, revenue $17.32B (MarketBeat; MarketBeat marks the date as estimated).
TRAI data
- Last 4 prints: avg |gap| 3.52% (1.63 ATR), fill 25%; all four gapped down (−2.3, −7.0, −2.9, −1.9%). GILD's beat-and-raise tonight (+2.2% after hours) is the closest peer read (S-073).
Linkages
- See Business line (TRAI /api/correlations 60d to 2026-10-22, stale).
2026-10-30 09:00 update
- Q3 2026 (Fri 10-30 BMO): revenue $17.404B vs $17.36B; adj. EPS $3.82 vs $3.74; Skyrizi $5.776B (+22.7%), Rinvoq $2.706B (+23.9%), Humira $683M (−31.2%). FY26 adj. EPS raised to $13.95–13.99, midpoint ≈ consensus (AbbVie, 2026-10-30).
- Premarket −0.27% (09:18). Neutral read-through to GILD (ρ 0.59).